Thrombopoietin in normal and neoplastic stem cell development

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 4, 2009, Pages 495-499

  Kaushansky, Kenneth ^a   Ranney, Helen M ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

c MPL; HOX; JAK2; myeloproliferative disorders; stem cell; thrombopoietin

Indexed keywords

INTERLEUKIN 3 RECEPTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; THROMBOPOIETIN; TRANSCRIPTION FACTOR FKHRL1; VASCULOTROPIN;

CANCER STEM CELL; CELL EXPANSION; CELL RENEWAL; CELL SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SOMATIC MUTATION; THROMBOCYTOPOIESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; HEMATOPOIETIC STEM CELLS; HUMANS; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN; THROMBOPOIETIN;

EID: 71749092866     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.08.004     Document Type: Review

References (34)

1. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 115 (2005) 3339-3347
2. Bussel J.B., Cheng G., Saleh M.N., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 (2007) 2237-2247
3. Kuter D.J., Bussel J.B., Lyons R.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371 (2008) 395-403
4. Sitnicka E., Lin N., Priestley G.V., et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 87 (1996) 4998-5005
5. Ku H., Yonemura Y., Kaushansky K., et al. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 87 (1996) 4544-4551
6. Solar G.P., Kerr W.G., Zeigler F.C., et al. Role of c-mpl in early hematopoiesis. Blood 92 (1998) 4-10
7. Fox N., Priestley G., Papayannopoulou T., et al. Thrombopoietin expands hematopoietic stem cells after transplantation. J Clin Invest 110 (2002) 389-394
8. Kaushansky K., Lin N., Grossmann A., et al. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 24 (1996) 265-269
9. Akahori H., Shibuya K., Obuchi M., et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 94 (1996) 722-728
10. Drachman J.G., Griffin J.D., and Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 270 (1995) 4979-4982
11. Drachman J.G., Millett K.M., and Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 274 (1999) 13480-13484
12. Geddis A.E., Fox N.E., and Kaushansky K. Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J Biol Chem 276 (2001) 34473-34479
13. Rojnuckarin P., Miyakawa Y., Fox N.E., et al. The roles of phosphatidylinositol 3-kinase and protein kinase Czeta for thrombopoietin-induced mitogen-activated protein kinase activation in primary murine megakaryocytes. J Biol Chem 276 (2001) 41014-41022
14. Pallard C., Gouilleux F., Benit L., et al. Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J 14 (1995) 2847-2856
15. Botas J. Control of morphogenesis and differentiation by HOM/Hox genes. Curr Opin Cell Biol 5 (1993) 1015-1022
16. Antonchuk J., Sauvageau G., and Humphries R.K. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 109 (2002) 39-45
17. Lawrence H.J., Helgason C.D., Sauvageau G., et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood 89 (1997) 1922-1930
18. Kirito K., Fox N., and Kaushansky K. Thrombopoietin stimulates Hoxb4 expression: an explanation for the favorable effects of TPO on hematopoietic stem cells. Blood 102 (2003) 3172-3178
19. Kirito K., Fox N., and Kaushansky K. Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: potential mechanism by which the hormone favorably affects hematopoietic stem cells. Mol Cell Biol 24 (2004) 6751-6762
20. Gerber H.P., Malik A.K., Solar G.P., et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417 (2002) 954-958
21. Kirito K., Fox N., Komatsu N., et al. Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1alpha. Blood 105 (2005) 4258-4263
22. Yoshida K., Kirito K., Yongzhen H., et al. Thrombopoietin (TPO) regulates HIF-1alpha levels through generation of mitochondrial reactive oxygen species. Int J Hematol 88 (2008) 43-51
23. Dijkers P.F., Medema R.H., Pals C., et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20 (2000) 9138-9148
24. Nakao T., Geddis A.E., Fox N.E., et al. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7 (2008) 257-266
25. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
26. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
27. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
28. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
29. Roder S., Steimle C., Meinhardt G., et al. STAT3 is constitutively active in some patients with polycythemia rubra vera. Exp Hematol 29 (2001) 694-702
30. Silva M., Richard C., Benito A., et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338 (1998) 564-571
31. Dai C., Chung I.J., and Krantz S.B. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol 33 (2005) 152-158
32. Lu X., Levine R., Tong W., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 102 (2005) 18962-18967
33. Li Y., Hetet G., Kiladjian J.J., et al. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Haematol 92 (1996) 60-66
34. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) e270